Kisqali + Faslodex Improves Survival in Advanced, HR+, HER2- BC

Options
Moderators
Moderators Member Posts: 25,912

Kisqali Plus Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer
October 2, 2019

Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy. Read more...

Categories